Biotech Roundup: GSK’s Ante, Shakeup at Sage, Telehealth’s Rise & More
Summary
—Dynacure raised a $55 million Series C financing round to advance its lead drug candidate, a treatment for a group of rare genetic muscle disorders, and expand the program to pediatric patients. —Gilead Sciences (NASDAQ: GILD) is paying South San Francisco-based microbiome drug developer Second Genome $38 million up front in a partnership intended to bolster its pipeline of treatments for inflammatory diseases. —A potential treatment for rare genetic condition Prader-Willi syndrome developed by Ann Arbor, MI-based Millendo Therapeutics (NASDAQ: MIND) failed to beat a placebo in a pivotal trial. —Luspatercept (Rebloyzl), a drug from Acceleron Pharma (NASDAQ: XLRN) and Bristol Myers Squibb (NYSE: BMY) won an additional FDA approval as a treatment for anemia in patients who have myelodysplastic syndromes. —The European Commission approved Takeda Pharmaceutical (NYSE: TAK) drug brigatinib (Alunbrig) as a primary treatment for adults with advanced non-small cell lung cancer (NSCLC) whose tumors overexpress the anaplastic lymphoma kinase (ALK) gene.
Classifications
AskAI Classifications
LabelsLinked Companies
